» Articles » PMID: 32583479

Stratification of Fabry Mutations in Clinical Practice: a Closer Look at α-galactosidase A-3D Structure

Overview
Journal J Intern Med
Specialty General Medicine
Date 2020 Jun 26
PMID 32583479
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fabry disease (FD) is an X-linked lysosomal storage and multi-system disorder due to mutations in the α-galactosidase A (α-GalA) gene. We investigated the impact of individual amino acid exchanges in the α-GalA 3D-structure on the clinical phenotype of FD patients.

Patients And Methods: We enrolled 80 adult FD patients with α-GalA missense mutations and stratified them into three groups based on the amino acid exchange location in the α-GalA 3D-structure: patients with active site mutations, buried mutations and other mutations. Patient subgroups were deep phenotyped for clinical and laboratory parameters and FD-specific treatment.

Results: Patients with active site or buried mutations showed a severe phenotype with multi-organ involvement and early disease manifestation. Patients with other mutations had a milder phenotype with less organ impairment and later disease onset. α-GalA activity was lower in patients with active site or buried mutations than in those with other mutations (P < 0.01 in men; P < 0.05 in women) whilst lyso-Gb3 levels were higher (P < 0.01 in men; <0.05 in women).

Conclusions: The type of amino acid exchange location in the α-GalA 3D-structure determines disease severity and temporal course of symptom onset. Patient stratification using this parameter may become a useful tool in the management of FD patients.

Citing Articles

Dorsal root ganglion magnetic resonance imaging biomarker correlations with pain in Fabry disease.

Schindehutte M, Weiner S, Klug K, Holzli L, Nauroth-Kress C, Hessenauer F Brain Commun. 2024; 6(3):fcae155.

PMID: 38751382 PMC: 11095551. DOI: 10.1093/braincomms/fcae155.


Small fibre neuropathy in Fabry disease: a human-derived neuronal disease model and pilot data.

Klein T, Gruner J, Breyer M, Schlegel J, Schottmann N, Hofmann L Brain Commun. 2024; 6(2):fcae095.

PMID: 38638148 PMC: 11024803. DOI: 10.1093/braincomms/fcae095.


characterization of cells derived from a patient with the variant c.376A>G (p.S126G) highlights a non-pathogenic role in Fabry disease.

Breyer M, Gruner J, Klein A, Finke L, Klug K, Sauer M Mol Genet Metab Rep. 2024; 38:101029.

PMID: 38469097 PMC: 10926200. DOI: 10.1016/j.ymgmr.2023.101029.


α-Gal A missense variants associated with Fabry disease can lead to ER stress and induction of the unfolded protein response.

Consolato F, De Fusco M, Schaeffer C, Pieruzzi F, Scolari F, Gallieni M Mol Genet Metab Rep. 2022; 33:100926.

PMID: 36345359 PMC: 9636577. DOI: 10.1016/j.ymgmr.2022.100926.


X-chromosomal inactivation patterns in women with Fabry disease.

Wagenhauser L, Rickert V, Sommer C, Wanner C, Nordbeck P, Rost S Mol Genet Genomic Med. 2022; 10(9):e2029.

PMID: 35971858 PMC: 9482401. DOI: 10.1002/mgg3.2029.